Annual Report 2024/25 - Growing revenue and EBITDA

Core Insights - ChemoMetec reported a revenue growth of 22% to DKK 495.6 million for the financial year 2024/25, with EBITDA increasing by 39% to DKK 258.0 million, driven by strong sales across instruments, consumables, and services [1][8]. Financial Performance - Revenue for 2024/25 reached DKK 495.6 million, with a 22% increase compared to the previous year, and this growth was consistent in both Danish kroner and at constant exchange rates [8]. - The EBITDA for the year was DKK 258.0 million, up from DKK 186.2 million in 2023/24, primarily due to increased revenue without a corresponding rise in costs, despite non-recurring restructuring costs of DKK 11.8 million impacting the results [8]. - The EBITDA margin improved to 52% from 46% in the previous year, and the profit for the year rose by DKK 50.1 million to DKK 186.4 million [8]. - The company proposed a dividend of DKK 7.0 per share, totaling DKK 121.8 million for the financial year [8]. Product Development and Market Strategy - ChemoMetec is focusing on launching new high-tech XcytoMatic products, with the XcytoMatic 40 targeting the bioprocessing market and the XcytoMatic 30 and 50 aimed at automation needs in cell and gene therapy [2][4]. - The company is confident in its market position within the automation sector and plans to accelerate marketing efforts for new products while continuing to develop additional solutions like the Sample Management System [3][4]. - The validation and decision-making process for the new XcytoMatic instruments is expected to be lengthy, requiring patience to realize their full potential [5]. Market Guidance - For the financial year 2025/26, ChemoMetec anticipates revenue between DKK 545 million and DKK 565 million, with EBITDA projected in the range of DKK 295 million to DKK 315 million [7]. Geographic Revenue Distribution - In the 2024/25 financial year, 59% of ChemoMetec's revenue was generated from the USA/Canada, 32% from Europe, and 9% from the rest of the world, showing no change from the previous year [8]. Conference Call Announcement - A conference call is scheduled for 12 September 2025, where the CEO and CFO will present the annual report for 2024/25 [9].